+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Dyslipidemia - Pipeline Review, H2 2019

  • ID: 4866578
  • Drug Pipelines
  • November 2019
  • Region: Global
  • 356 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • 89bio Ltd
  • AstraZeneca Plc
  • Daiichi Sankyo Co Ltd
  • Hanlim Pharm Co Ltd
  • Micelle BioPharma Inc
  • OncoImmune Inc
  • MORE
Dyslipidemia - Pipeline Review, H2 2019

Summary

This latest Pharmaceutical and Healthcare disease pipeline guide Dyslipidemia - Pipeline Review, H2 2019, provides an overview of the Dyslipidemia (Metabolic Disorders) pipeline landscape.

Dyslipidemia is defined as elevation of the total cholesterol, the "bad" low-density lipoprotein (LDL) cholesterol and the triglyceride concentrations, and a decrease in the "good" high-density lipoprotein (HDL) cholesterol concentration in the blood. Numerous factors and causes can lead to an abnormality in the levels of lipids in the blood such as genetic predisposition, diet, age and gender, type II diabetes. Common symptoms that may be encountered in relation to dyslipidemia include corneal opacification, corneal arcus, xanthomas, balance impairment, pain in the calf when walking, dizziness and confusion.

Report Highlights

This Pharmaceutical and Healthcare latest pipeline guide Dyslipidemia - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Dyslipidemia (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Dyslipidemia (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Dyslipidemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 6, 26, 16, 26, 33, 7 and 2 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 12 and 4 molecules, respectively.

Dyslipidemia (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher'sproprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Dyslipidemia (Metabolic Disorders).
  • The pipeline guide reviews pipeline therapeutics for Dyslipidemia (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Dyslipidemia (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Dyslipidemia (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Dyslipidemia (Metabolic Disorders)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Dyslipidemia (Metabolic Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Dyslipidemia (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • 89bio Ltd
  • AstraZeneca Plc
  • Daiichi Sankyo Co Ltd
  • Hanlim Pharm Co Ltd
  • Micelle BioPharma Inc
  • OncoImmune Inc
  • MORE
Introduction
Dyslipidemia - Overview
Dyslipidemia - Therapeutics Development
Dyslipidemia - Therapeutics Assessment
Dyslipidemia - Companies Involved in Therapeutics Development
Dyslipidemia - Drug Profiles
Dyslipidemia - Dormant Projects
Dyslipidemia - Discontinued Products
Dyslipidemia - Product Development Milestones
Appendix

List of Tables
Table 1: Number of Products under Development for Dyslipidemia, H2 2019
Table 2: Number of Products under Development by Companies, H2 2019
Table 3: Number of Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Table 4: Number of Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Table 5: Number of Products under Development by Companies, H2 2019 (Contd..3), H2 2019
Table 6: Number of Products under Development by Universities/Institutes, H2 2019
Table 7: Products under Development by Companies, H2 2019
Table 8: Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Table 9: Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Table 10: Products under Development by Companies, H2 2019 (Contd..3), H2 2019
Table 11: Products under Development by Companies, H2 2019 (Contd..4), H2 2019
Table 12: Products under Development by Companies, H2 2019 (Contd..5), H2 2019
Table 13: Products under Development by Companies, H2 2019 (Contd..6), H2 2019
Table 14: Products under Development by Universities/Institutes, H2 2019
Table 15: Number of Products by Stage and Target, H2 2019
Table 16: Number of Products by Stage and Target, H2 2019 (Contd..1), H2 2019
Table 17: Number of Products by Stage and Mechanism of Action, H2 2019
Table 18: Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..1), H2 2019
Table 19: Number of Products by Stage and Route of Administration, H2 2019
Table 20: Number of Products by Stage and Molecule Type, H2 2019
Table 21: Dyslipidemia - Pipeline by 89bio Ltd, H2 2019
Table 22: Dyslipidemia - Pipeline by AbbVie Inc, H2 2019
Table 23: Dyslipidemia - Pipeline by ABIONYX Pharma SA, H2 2019
Table 24: Dyslipidemia - Pipeline by Acasti Pharma Inc, H2 2019
Table 25: Dyslipidemia - Pipeline by AD Pharmaceuticals Co Ltd, H2 2019
Table 26: Dyslipidemia - Pipeline by Affina Biotechnologies Inc, H2 2019
Table 27: Dyslipidemia - Pipeline by Akcea Therapeutics Inc, H2 2019
Table 28: Dyslipidemia - Pipeline by Akeso Biopharma Inc, H2 2019
Table 29: Dyslipidemia - Pipeline by Amarin Corp Plc, H2 2019
Table 30: Dyslipidemia - Pipeline by Arrowhead Pharmaceuticals Inc, H2 2019
Table 31: Dyslipidemia - Pipeline by AstraZeneca Plc, H2 2019
Table 32: Dyslipidemia - Pipeline by AVVA Pharmaceuticals AG, H2 2019
Table 33: Dyslipidemia - Pipeline by BCWorld Pharm Co Ltd, H2 2019
Table 34: Dyslipidemia - Pipeline by BioRestorative Therapies Inc, H2 2019
Table 35: Dyslipidemia - Pipeline by Boryung Pharmaceutical Co Ltd, H2 2019
Table 36: Dyslipidemia - Pipeline by Cadila Healthcare Ltd, H2 2019
Table 37: Dyslipidemia - Pipeline by Cadila Pharmaceuticals Ltd, H2 2019
Table 38: Dyslipidemia - Pipeline by Cardax Inc, H2 2019
Table 39: Dyslipidemia - Pipeline by Celon Pharma SA, H2 2019
Table 40: Dyslipidemia - Pipeline by Centaurus Therapeutics Inc, H2 2019
Table 41: Dyslipidemia - Pipeline by Centeer BioTherapeutics Ltd Co, H2 2019
Table 42: Dyslipidemia - Pipeline by Chong Kun Dang Pharmaceutical Corp, H2 2019
Table 43: Dyslipidemia - Pipeline by CJ HealthCare Corp, H2 2019
Table 44: Dyslipidemia - Pipeline by Corbus Pharmaceuticals Inc, H2 2019
Table 45: Dyslipidemia - Pipeline by Corvidia Therapeutics Inc, H2 2019
Table 46: Dyslipidemia - Pipeline by CVI Pharmaceuticals US Inc, H2 2019
Table 47: Dyslipidemia - Pipeline by Daewon Pharmaceutical Co Ltd, H2 2019
Table 48: Dyslipidemia - Pipeline by Daewoong Pharmaceutical Co Ltd, H2 2019
Table 49: Dyslipidemia - Pipeline by Daiichi Sankyo Co Ltd, H2 2019
Table 50: Dyslipidemia - Pipeline by Delivra Corp, H2 2019
Table 51: Dyslipidemia - Pipeline by DongKoo Bio & Pharma Co Ltd, H2 2019
Table 52: Dyslipidemia - Pipeline by Eli Lilly and Co, H2 2019
Table 53: Dyslipidemia - Pipeline by Elyson Pharmaceutical Co Ltd, H2 2019
Table 54: Dyslipidemia - Pipeline by Esperion Therapeutics Inc, H2 2019
Table 55: Dyslipidemia - Pipeline by Gemphire Therapeutics Inc, H2 2019
Table 56: Dyslipidemia - Pipeline by Gilead Sciences Inc, H2 2019
Table 57: Dyslipidemia - Pipeline by Golden Biotechnology Corp, H2 2019
Table 58: Dyslipidemia - Pipeline by Handok Inc, H2 2019
Table 59: Dyslipidemia - Pipeline by Hanlim Pharm Co Ltd, H2 2019
Table 60: Dyslipidemia - Pipeline by Hanmi Pharmaceuticals Co Ltd, H2 2019

List of Figures
Figure 1: Number of Products under Development for Dyslipidemia, H2 2019
Figure 2: Number of Products under Development by Companies, H2 2019
Figure 3: Number of Products under Development by Universities/Institutes, H2 2019
Figure 4: Number of Products by Top 10 Targets, H2 2019
Figure 5: Number of Products by Stage and Top 10 Targets, H2 2019
Figure 6: Number of Products by Top 10 Mechanism of Actions, H2 2019
Figure 7: Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019
Figure 8: Number of Products by Routes of Administration, H2 2019
Figure 9: Number of Products by Stage and Routes of Administration, H2 2019
Figure 10: Number of Products by Top 10 Molecule Types, H2 2019
Figure 11: Number of Products by Stage and Top 10 Molecule Types, H2 2019
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • 89bio Ltd
  • AbbVie Inc
  • ABIONYX Pharma SA
  • Acasti Pharma Inc
  • AD Pharmaceuticals Co Ltd
  • Affina Biotechnologies Inc
  • Akcea Therapeutics Inc
  • Akeso Biopharma Inc
  • Amarin Corp Plc
  • Arrowhead Pharmaceuticals Inc
  • AstraZeneca Plc
  • AVVA Pharmaceuticals AG
  • BCWorld Pharm Co Ltd
  • BioRestorative Therapies Inc
  • Boryung Pharmaceutical Co Ltd
  • Cadila Healthcare Ltd
  • Cadila Pharmaceuticals Ltd
  • Cardax Inc
  • Celon Pharma SA
  • Centaurus Therapeutics Inc
  • Centeer BioTherapeutics Ltd Co
  • Chong Kun Dang Pharmaceutical Corp
  • CJ HealthCare Corp
  • Corbus Pharmaceuticals Inc
  • Corvidia Therapeutics Inc
  • CVI Pharmaceuticals US Inc
  • Daewon Pharmaceutical Co Ltd
  • Daewoong Pharmaceutical Co Ltd
  • Daiichi Sankyo Co Ltd
  • Delivra Corp
  • DongKoo Bio & Pharma Co Ltd
  • Eli Lilly and Co
  • Elyson Pharmaceutical Co Ltd
  • Esperion Therapeutics Inc
  • Gemphire Therapeutics Inc
  • Gilead Sciences Inc
  • Golden Biotechnology Corp
  • Handok Inc
  • Hanlim Pharm Co Ltd
  • Hanmi Pharmaceuticals Co Ltd
  • Ildong Pharmaceutical Co Ltd
  • Inovio Pharmaceuticals Inc
  • InStar Technologies AS
  • Jeil Pharmaceutical Co Ltd
  • Jenrin Discovery Inc
  • Jiangsu Hengrui Medicine Co Ltd
  • Kolmar Pharma Co Ltd
  • Kotobuki Pharmaceutical Co Ltd
  • Kowa Co Ltd
  • Krisani Bio Sciences Pvt Ltd
  • Kuhnil Pharmaceutical Co Ltd
  • Kyorin Pharmaceutical Co Ltd
  • Kyung Dong Co Ltd
  • LG Chem Ltd
  • LipimetiX Development Inc
  • Matinas BioPharma Holdings Inc
  • Micelle BioPharma Inc
  • Mochida Pharmaceutical Co Ltd
  • MYR GmbH
  • Nippon Chemiphar Co Ltd
  • NorthSea Therapeutics BV
  • NovalGen Ltd
  • Novartis AG
  • NuSirt Biopharma Inc
  • Omeros Corp
  • OncoImmune Inc
  • Pfizer Inc
  • Pharmena SA
  • Regeneron Pharmaceuticals Inc
  • Reneo Pharmaceuticals Inc
  • Sequor Pharmaceuticals LLC
  • Shanghai Institute of Pharmaceutical Industry
  • Shanghai Junshi Bioscience Co Ltd
  • Shenzhen Salubris Pharmaceuticals Co Ltd
  • Shifa Biomedical Corp
  • SJT Molecular Research SL
  • Staten Biotechnology BV
  • Suzhou Ribo Life Sciences Co Ltd
  • Sveikatal Inc
  • Tetranov International Inc
  • Viking Therapeutics Inc
  • Yuhan Corp
Note: Product cover images may vary from those shown
Adroll
adroll